Open Access iconOpen Access

ARTICLE

crossmark

Benefit of prophylactic bronchodilator with β2 adrenergic agonist in ischemia-reperfusion-induced lung injury

CHEN-LIANG TSAI1, YU-HUEI LIN2, CHIH-YING CHANGCHIEN3, CHIH-FENG CHIAN1,#,*, CHI-HUEI CHIANG4,#,*

1 Division of Pulmonary and Critical Care, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan
2 Post-Baccalaureate Program in Nursing, College of Nursing, Taipei Medical University, Taipei, 110, Taiwan
3 Department of General Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan
4 Division of Pulmonary Immunology and Infectious Diseases, Chest Department, Taipei Veterans General Hospital, Taipei, 112, Taiwan

* Address correspondence to: Chi-Huei Chiang, email; Chih-Feng Chian, email
# These authors contributed equally to this work

(This article belongs to the Special Issue: Cellular Biomechanics in Health and Diseases)

BIOCELL 2021, 45(5), 1201-1211. https://doi.org/10.32604/biocell.2021.014279

Abstract

Primary lung graft dysfunction could significantly attribute to ischemia-reperfusion lung injury (IRLI) during transplantation surgery. β2-adrenergic agonists were one of the bronchodilators that had been well-established in the management of asthma and chronic obstructive pulmonary disease (COPD) with anti-inflammatory potency. By applying the model of isolated rat lung, we evaluated the efficacy of short-acting β2-agonist inhalation to ameliorate ischemia-reperfusion damage. The experiment protocol was 180 min of global ischemia and then reperfusion for 60 min. In the β2-agonist inhalation group, aerosolized albuterol was administrated prior ischemia procedure. Increased weight ratios of wet to dry lung and microvascular permeability were characterized in the IRLI group. In contrast, pre-inhaled β2-agonist significantly mitigated the severity of pulmonary edema. Bronchoalveolar lavage from the β2-agonist group presented decreased leukocyte counts and cytokines production, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and macrophage inflammatory protein 2 (MIP-2). Devastating oxidative stress was widely recognized during the ischemia-reperfusion process, while β2-agonist pretreatment revealed subsided H2O2, myeloperoxidase (MPO), and the cleavage of caspase-3. Western blotting from lung homogenates identified the blockade of NF-κB and MAPK activation in the β2-agonist inhalation group. Currently, there was no specific pharmacotherapy in IRLI management. Our results elucidated the protective effect of β2-agonist bronchodilator against ischemia-reperfusion induced oxidative stress, inflammation reaction, and pulmonary edema.

Keywords


Cite This Article

APA Style
TSAI, C., LIN, Y., CHANGCHIEN, C., CHIAN, C., CHIANG, C. (2021). Benefit of prophylactic bronchodilator with β2 adrenergic agonist in ischemia-reperfusion-induced lung injury. BIOCELL, 45(5), 1201-1211. https://doi.org/10.32604/biocell.2021.014279
Vancouver Style
TSAI C, LIN Y, CHANGCHIEN C, CHIAN C, CHIANG C. Benefit of prophylactic bronchodilator with β2 adrenergic agonist in ischemia-reperfusion-induced lung injury. BIOCELL . 2021;45(5):1201-1211 https://doi.org/10.32604/biocell.2021.014279
IEEE Style
C. TSAI, Y. LIN, C. CHANGCHIEN, C. CHIAN, and C. CHIANG "Benefit of prophylactic bronchodilator with β2 adrenergic agonist in ischemia-reperfusion-induced lung injury," BIOCELL , vol. 45, no. 5, pp. 1201-1211. 2021. https://doi.org/10.32604/biocell.2021.014279



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 3083

    View

  • 1406

    Download

  • 0

    Like

Share Link